Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.36255/exonpublications.prostatecancer.theranostics.2021 http://scihub22266oqcxt.onion/10.36255/exonpublications.prostatecancer.theranostics.2021 34181373!ä!34181373 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Prostate+Cancer-/-ä 2021 ; ä (ä): ä Nephropedia Template TP {{tp|p=34181373|t=2021. Theranostics in Metastatic Castrate Resistant Prostate Cancer |pdf=|usr=}}{{34181373}} gab.com Text Theranostics in Metastatic Castrate Resistant Prostate Cancer JO: Prostate Cancer-/-ä http://www.kidney.de/pget.php?&tw=1&pmid=34181373 #FOAvip Despite advances in the treatment of localized prostate cancer, many patients progress to metastatic castration-resistant prostate cancer with limited median survival benefits, and significant morbidity. Therefore, efforts to explore new therapeutic modalities for metastatic castration-resistant prostate cancer are urgently needed. A theranostic approach in oncology is based on the principle of imaging a particular molecular target with a diagnostic radioisotope, and then substituting it with a therapeutic isotope to treat a patient who demonstrates sufficient target expression on diagnostic images. Radioisotope pairs are usually chosen in such a way that their physical and chemical properties are similar to ensure the therapeutic agent will be distributed in the same way as the diagnostic agent. This chapter outlines the most recent advances in the use of prostate specific membrane antigen (PSMA) in theranostics with emphasis on (177)Lu-PSMA, (225)Ac-PSMA and (223)Ra-dicloride. The clinical utility of these radioisotopes along with their limitations and future perspectives are discussed. Twit Text FOAVip Theranostics in Metastatic Castrate Resistant Prostate Cancer ????Prostate Cancer-/-ä http://www.kidney.de/pget.php?&tw=1&pmid=34181373 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34181373 #FOAvip English Wikipedia <ref>{{Cite pmid|34181373}}</ref> Theranostics in Metastatic Castrate Resistant Prostate Cancer #MMPMID34181373 Vorster M; Sathekge MM Prostate Cancer-/-ä 2021[May]; ä (ä): ä PMID34181373show ga Despite advances in the treatment of localized prostate cancer, many patients progress to metastatic castration-resistant prostate cancer with limited median survival benefits, and significant morbidity. Therefore, efforts to explore new therapeutic modalities for metastatic castration-resistant prostate cancer are urgently needed. A theranostic approach in oncology is based on the principle of imaging a particular molecular target with a diagnostic radioisotope, and then substituting it with a therapeutic isotope to treat a patient who demonstrates sufficient target expression on diagnostic images. Radioisotope pairs are usually chosen in such a way that their physical and chemical properties are similar to ensure the therapeutic agent will be distributed in the same way as the diagnostic agent. This chapter outlines the most recent advances in the use of prostate specific membrane antigen (PSMA) in theranostics with emphasis on (177)Lu-PSMA, (225)Ac-PSMA and (223)Ra-dicloride. The clinical utility of these radioisotopes along with their limitations and future perspectives are discussed. äTheranostics in Metastatic Castrate Resistant Prostate Cancer (epmc).pdf DeepDyve Pubget Overpricing